The National Cancer Center on Thursday released three-year survival rates for four less common types of cancer: cancer of the kidneys, gallbladder, pharynx, and renal pelvis and ureter.

The survival rate for patients undergoing treatment stood at 85.6 percent for kidney cancer, 33.4 percent for gallbladder cancer, 84.4 percent for pharyngeal cancer and 55.6 percent for renal pelvis and ureter cancer, the center said.

This was the first disclosure of three-year survival rates for patients with the four types of cancer, which are less common than other types.

The center calculated the survival rates based on information gathered in 2012 from some 550,000 people who were diagnosed with cancer at 349 core hospitals that treat the disease.

The latest tally also showed that those who were diagnosed with cancer at early stages have higher survival rates.

Among patients with gallbladder cancer, the survival rate came to 91.1 percent for stage 1 patients and 77.4 percent for stage 2 patients.

The center will later release five-year survival rates for the four types of cancer.

The center also said that the five-year survival rate for all patients diagnosed with cancer in 2009 and 2010 stood at 58.6 percent.

By cancer type, the survival rate stood at 92.5 percent for breast cancer and 98.6 percent for prostate cancer.

Among more deadly types of cancer, pancreas cancer had a survival rate of 9.6 percent, liver cancer 40 percent, lung and throat cancer 40.6 percent, and esophagus cancer 44.4 percent.

The survival rate was 71.6 percent for stomach cancer, 72.9 percent for bowel cancer, 75.3 percent for cervix cancer, 82.1 percent for endometrial cancer and 69.5 percent for vesical cancer.

The center also said that the number of patients diagnosed with blood cancer in 2017 totaled 51,936, including 22,652 people with mature B-cell neoplasm. A total of 696 children up to 9 years old were diagnosed with blood cancer, including 381 with precursor lymphoid neoplasms.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.